Reuters logo
Novartis to buy France's Advanced Accelerator for $3.9 bln
October 30, 2017 / 6:31 AM / in a month

Novartis to buy France's Advanced Accelerator for $3.9 bln

ZURICH, Oct 30 (Reuters) - Swiss drugmaker Novartis on Monday said it was buying France’s Advanced Accelerator Applications (AAA) in a $3.9 billion cash deal to strengthen the oncology portfolio at the world’s biggest maker of prescription medicines.

Basel-based Novartis is offering $41 per ordinary share and $82 per American depositary share for AAA, which makes radiopharmaceuticals including the product Lutathera that are used for both diagnosis and therapy. (Reporting by John Miller; Editing by Michael Shields)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below